For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients
To truly expand CAR T access and prepare for the wave of new T cell-based therapies coming through the pipeline, we must find better ways to manage CRS and ICANS.
To truly expand CAR T access and prepare for the wave of new T cell-based therapies coming through the pipeline, we must find better ways to manage CRS and ICANS.
This ability to closely monitor patients remotely is redefining the standard of care, especially for those managing complex health conditions. RPM technology provides timely insights that allow healthcare teams to intervene early, improve patient outcomes, and reduce the burden on hospital resources.
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
The company plans to use the funding to advance LYR-210 into a Phase II clinical trial and also explore its development platform in other ENT diseases.